Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $16.52 on Wednesday. The company has a 50 day simple moving average of $19.18 and a 200 day simple moving average of $17.04. The firm has a market cap of $503.36 million, a PE ratio of 10.73 and a beta of 0.86. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $22.55.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Keros Therapeutics in the 1st quarter valued at approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after buying an additional 2,982 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares during the last quarter. Creative Planning increased its stake in shares of Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after buying an additional 6,948 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Keros Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after buying an additional 7,146 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Ratings Changes

KROS has been the subject of several analyst reports. Zacks Research lowered Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Bank of America boosted their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.29.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.